The rotation reflects a change in what investors are rewarding. Companies with steadier earnings and established cash flows have become more attractive as the market questions whether spending on AI infrastructure will deliver returns quickly enough to justify its cost.
Reuters reported that healthcare led the S&P 500’s 11 major sectors on October 20, reaching a record high. The Dow Jones Industrial Average gained 1.02% to 52,495.88, while the S&P 500 rose 0.28% to 7,712.57. The Nasdaq Composite slipped 0.02% to 26,424.82. The S&P 500 value index gained 0.9%, compared with a 0.2% decline in its growth counterpart, according to Reuters.
Drugmakers have been among the sector’s strongest performers. Eli Lilly rose 3.49% on October 20 to close at $1,283.66, approaching its 52-week high, as investors continued to focus on its obesity and diabetes treatments. The company’s growth prospects have also been supported by demand for its GLP-1 medicines and its broader pipeline of cardiometabolic drugs.
Johnson & Johnson and Merck (NYSE: MRK) are attracting attention for different reasons. J&J has been expanding its immunology portfolio, while Merck is working to develop new oncology products ahead of the anticipated loss of exclusivity for its blockbuster cancer drug Keytruda in 2028. The prospect of new treatments and acquisitions has helped improve sentiment across the pharmaceutical industry.
Goldman Sachs pharmaceutical analyst Asad Haider said he remained constructive on the sector heading into 2027, with Eli Lilly, J&J and Merck among his preferred large-cap names. Barron’s report on the pharma outlook highlighted clinical progress and dealmaking as important supports, despite interest-rate and political uncertainty.
The broader rally has also included healthcare companies outside traditional pharmaceuticals. Medical-device manufacturers such as Stryker (NYSE: SYK), Abbott Laboratories (NYSE: ABT) and Zimmer Biomet (NYSE: ZBH) have drawn investor interest as Wall Street reassesses valuations across the sector. The recent earnings reaction at Intuitive Surgical (NASDAQ: ISRG) illustrates why company-level fundamentals still matter: its quarterly results beat estimates, but planned instrument price reductions and a legal settlement weighed on the stock.
Valuations are changing, too. The Wall Street Journal reported on October 21 that healthcare stocks had shed their longstanding discount to the wider market and were trading at approximately 19.3 times forward earnings, slightly above the S&P 500. The premium suggests investors are increasingly willing to pay for more predictable profits, although it also means the sector is no longer uniformly cheap.
The improvement builds on a broader run in healthcare names that have outperformed the market while AI stocks dominate investor attention. But the current rally is not driven by one common catalyst. Drugmakers benefit from product launches and clinical progress, medical-device companies depend on procedure volumes and hospital spending, and health insurers remain exposed to reimbursement rates and government policy.
Is Healthcare Replacing AI as Wall Street’s Next Big Trade?
The recent gains suggest investors are diversifying their exposure, not abandoning artificial intelligence. Reuters documented a similar shift on October 15, when concerns about debt-heavy AI companies and higher borrowing costs sent investors toward Eli Lilly, UnitedHealth and other defensive stocks. Healthcare gained 1.84% that day, while the Philadelphia semiconductor index fell for a seventh consecutive session.
That pattern reflects a wider effort to distinguish companies that can fund their expansion internally from businesses more dependent on financing conditions. As investors reassess the stocks driving Wall Street’s rally, the quality of earnings and cash flow is becoming a more important factor alongside headline growth.
Still, there are reasons to be cautious about calling healthcare the new AI trade. Pharma companies face drug-pricing pressure and the risk that clinical trials fail. Patent expirations can expose revenue gaps, as Merck’s Keytruda timetable demonstrates. Insurers face uncertainty around government reimbursement and healthcare costs, while medical-device makers can be affected by hospital budgets and procedure trends.
The sector’s rising valuation also narrows the margin for disappointment. A higher price-to-earnings multiple can leave shares vulnerable if sales forecasts weaken or a drug fails to meet expectations. Investors should therefore avoid assuming that every healthcare stock will benefit equally from a shift toward defensive businesses.
AI and healthcare are also not mutually exclusive. Pharmaceutical companies increasingly use AI in drug discovery, clinical research and operational processes. Technology can become a tool for healthcare businesses even as investors seek to reduce exposure to expensive AI infrastructure providers.
The market’s next test will be whether healthcare companies can maintain earnings growth while broader economic and financing conditions remain uncertain. Results, guidance and developments in drug pipelines will matter more than the sector label alone.
For investors considering how to allocate across market sectors, the recent rotation is a reminder to focus on business fundamentals rather than treating a popular market theme as permanent. Healthcare may offer a more defensive source of earnings in a volatile market, but it is not immune to valuation risk or company-specific setbacks.
The evidence points to a growing role for healthcare in Wall Street’s search for durable profits. It does not yet establish that the sector will replace AI as the market’s dominant investment theme. For now, investors appear to be broadening their choices as they become more selective about where future growth is likely to come from.